adamantane has been researched along with Carcinoma, Pancreatic Ductal in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anders, R; Begum, A; Chang, YT; Ewachiw, T; Gocke, C; Li, J; Maitra, A; Marchionni, L; Matsui, W; McMillan, RH; Penchev, VR; Rasheed, Z; Uren, A; Wang, Q | 1 |
| Giannuzzo, A; Novak, I; Pedersen, SF | 1 |
| Alves, F; Ellegaard, M; Giannuzzo, A; Napp, J; Novak, I; Saccomano, M | 1 |
3 other study(ies) available for adamantane and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma.
Topics: Actins; Adamantane; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytoskeletal Proteins; Heterografts; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolines | 2019 |
The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.
Topics: Adamantane; Adenosine Triphosphate; Aminoquinolines; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Purinergic P2X Receptor Agonists; Purinergic P2X Receptor Antagonists; Pyridines; Receptors, Purinergic P2X7; Tetrazoles | 2015 |
Targeting of the P2X7 receptor in pancreatic cancer and stellate cells.
Topics: Adamantane; Aminoquinolines; Animals; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Heterografts; Humans; Luminescent Measurements; Male; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, Purinergic P2X7 | 2016 |